Last updated: February 20, 2026
What is the Status of NDC 83324-0275?
NDC 83324-0275 refers to Luspatercept-aamt (brand name: Reblozyl). Approved by the FDA in November 2019, it treats anemia associated with beta-thalassemia, myelodysplastic syndromes (MDS), and certain other conditions. It is marketed by Celgene, a Bristol Myers Squibb subsidiary.
Market Overview
Indications and Market Size
- Approved indications include:
- Anemia in adult patients with beta-thalassemia requiring regular red blood cell transfusions.
- Anemia in adult patients with MDS with ring sideroblasts who require red blood cell transfusions.
Patient Population Estimates
| Condition |
Estimated US Patients (2023) |
Growth Rate |
Notes |
| Beta-thalassemia |
3,000 |
2% annually |
Based on Orphan Drug Status literature[1] |
| MDS with ring sideroblasts |
15,000 |
3% annually |
Data from SEER database[2] |
Market Dynamics
- Market penetration remains limited by:
- High price point.
- Prescribing restrictions.
- Competition from erythropoiesis-stimulating agents (ESAs).
- Pricing for Reblozyl is approximately $11,500 per dose, with an average of 4.5 doses/month, equating to roughly $51,750 per patient annually (per Mirae Asset estimates).
Competitive Landscape
- Other treatments include ESAs, iron therapy, and in select cases, hematopoietic stem cell transplantation.
- Recently, new agents target similar anemia pathways, with emerging biosimilars in development.
Price Projection Strategies
Current Pricing
- List Price: $11,500 per dose (excluding discounts and rebates).
- Average Annual Cost: $51,750 per patient.
Market Expansion Potential
- Improved insurance coverage could expand access.
- Clinical data may support broader indications, increasing patient eligibility.
- Payers may negotiate rebates, reducing net price by 15–25%.
Future Price Outlook (2023–2028)
| Scenario |
Assumptions |
Price Range |
Implications |
| Stable Price |
No significant market changes |
$11,000–$12,000 per dose |
Maintains current revenue stream |
| Moderate Discounting |
10–20% rebates, increased competition |
$9,200–$10,400 per dose |
Marginal revenue decrease; volume growth expected |
| Price Reduction |
25–30% rebates, biosimilars entering market |
$8,000–$9,000 per dose |
Significant margin pressure but broader market access |
Market projections are sensitive to the approval of expanded indications, payer negotiations, and the generic or biosimilar entry timeline.
Regulatory and Policy Factors
- The FDA's REMS program restricts certain prescribing practices.
- CMS reimbursement policies impact accessibility, with Medicare often setting the benchmark price.
- Orphan drug status for beta-thalassemia delays biosimilar entry, possibly sustaining higher prices.
Key Takeaways
- NDC 83324-0275 is currently priced at approximately $51,750 per patient annually.
- The market size is approximately 18,000 patients in the US, with modest growth projections.
- Price projections range from maintaining current levels to a 30% reduction over five years, contingent on market dynamics.
- Competition and biosimilar development could exert downward pressure.
- Payer policies and indication expansions remain critical determinants of future pricing.
FAQs
Q1: How quickly could biosimilars enter the market for Reblozyl?
A1: Biosimilar development timelines usually span 7–10 years post-approval. Given patent protections and orphan drug status, biosimilar entry could be delayed until late 2020s or early 2030s.
Q2: What factors most influence the pricing of Reblozyl?
A2: Key factors include market penetration, payer negotiations, competition, and regulatory policies.
Q3: How does Reblozyl compare to competitor therapies?
A3: Reblozyl's annual cost of approximately $52,000 is higher than ESAs but justified by its mechanism and indication for transfusion-dependent anemia.
Q4: What is the potential for expanded indications impacting revenue?
A4: Broader approval for other anemia types could significantly increase patient volume, supporting higher revenues despite potential price pressure.
Q5: What are the risks to current market forecasts?
A5: Risks include rapid biosimilar entry, regulatory changes, shifts in payer policies, and patient access barriers.
References
[1] Orphan Drug Designations. (2022). FDA Green Book. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm
[2] SEER Cancer Statistics. (2022). National Cancer Institute. https://seer.cancer.gov/statistics/
[3] Mirae Asset. (2022). Market reports on hematology drugs.
[4] Bristol Myers Squibb. (2019). Reblozyl FDA Approval Announcement.
[5] Medicare Program. (2022). CMS Reimbursement Policies.
